Molecular modelling of human CYP2E1 by homology with the CYP102 haemoprotein domain: Investigation of the interactions of substrates and inhibitors within the putative active site of the human CYP2E1 isoform

Xenobiotica

Volumn 30, Issue 1, 2000, Pages 1-25

  Lewis, D F V ^a   Bird, M G ^b   Dickins, M ^c   Lake, B G ^d   Eddershaw, P J ^c   Tarbit, M H ^c   Goldfarb, P S ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b EXXONMOBIL UPSTREAM RESEARCH COMPANY   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d BIBRA INTERNATIONAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BACTERIAL PROTEIN; DIMETHYLNITROSAMINE DEMETHYLASE; ENZYME INHIBITOR; HEMOPROTEIN;

ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME SUBSTRATE; HYDROGEN BOND; MOLECULAR MODEL; MOLECULAR WEIGHT; ORIENTATION; PROTEIN BINDING; PROTEIN METABOLISM; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS;

BACTERIA (MICROORGANISMS);

EID: 0033958217     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982500237794     Document Type: Article

References (81)

1. Amet, Y., Lucas, D., Zhang-Gouillon, Z.-Q. and French, S. W., 1998, P450-dependent metabolism of lauric acid in alcoholic liver disease: comparison between rat and kidney microsomes. Alcoholism: Clinical and Experimental Research, 22, 455-462.
2. Ardies, C. M., Zachman, E. K. and Koehn, B. J., 1994, Effect of swimming exercise and ethanol on rat liver P450-dependent monooxygenases. Medicine and Science in Sports and Exercise, 26, 1453-1458.
3. Barnett, C. R., Flatt, P. R. and Ioannides, C., 1994, Modulation of the rat hepatic cytochrome P450 composition by long-term streptozotocin-induced insulin-dependent diabetes. Journal of Biochemical Toxicology, 9, 63-69.
4. Bellward, G. D., Chang, T., Rodrigues, B., McNeill, J. H., Maines, S., Levin, W. and Thomas, P. E., 1988, Hepatic cytochrome P450j induction in the spontaneously diabetic BB rat. Molecular Pharmacology, 33, 140-143.
5. Bond, J. A., Recio, L. and Andjelkovich, D., 1995, Epidemiological and mechanistic data suggest that 1,3-butadiene will not be carcinogenic to humans at exposures likely to be encountered in the environment or workplace. Carcinogenesis, 16, 165-171.
6. Brady, J. F., Ishizaki, H., Fukuto, J. M., Lin, M. C., Fadel, A., Gapac, J. M. and Yang, C. S., 1991, Inhibition of cytochrome P450 2E1 by diallyl sulphide and its metabolites. Chemical Research in Toxicology, 4, 642-647.
7. Cederbaum, A. I., 1987, Microsomal generation of hydroxyl radicals: its role in microsomal ethanol oxidizing system (MEOS) activity and requirement for iron. Annals of the New York Academy of Sciences, 492, 35-49.
8. Chen, T. L., Ueng, T. H., Chen, S. H., Lee, P. H., Dan, S. Z. and Liu, C. C., 1995, Human cytochrome P450 mono-oxygenase system is suppressed by propofol. British Journal of Anaesthesia, 74, 558-562.
9. Csanady, G. A., Guengerich, F. P. and Bond, J. A., 1992, Comparison of the biotransformation of 1,3-butadiene and its metabolite butadiene monoepoxide by hepatic and pulmonary tissues from humans, rats and mice. Carcinogenesis, 13, 1143-1153.
10. Dresibach, A. W., Fertencz, N., Hopkins, N. E., Fuentes, M. G., Rege, A. B., George, W. J. and Lertora, J. J. L., 1996, Urinary excretion of 6-hydroxychlorozoxazone (CXZ-OH, as an index of cytochrome P450 2E1 activity. Clinical Pharmacology and Therapeutics, 58, 498-505.
11. Duescher, R. J. and Elfarra, A. A., 1994, Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1. Archives of Biochemistry and Biophysics, 311, 342-349.
12. Elkstrom, G., Cronholm, T. and Ingelman-Sundberg, M., 1986, Hydroxyl radical production and ethanol oxidation by liver microsomes from ethanol-treated rats. Biochemical Journal, 233, 755-761.
13. Fukuda, T., Imai, Y., Komori, M., Nakamura, M., Kusunose, E., Satouchi, K. and Kusunose, M., 1993, Replacement of Thr-303 of P450 2E1 with serine modifies the regioselectivity of its fatty acid hydroxylase activity. Journal of Biochemistry, 113, 7-12.
14. Gonzalez, F. J. and Gelboin, H. V., 1994, Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metabolism Reviews, 26, 165-183.
15. Gotoh, O., 1992, Substrate recognition sites in cytochrome P450 family 2 (CYP2, inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry, 267, 83-90.
16. Graham-Lorence, S., Truan, G., Peterson, J. A., Falck, J. R., Wei, S., Helvig, C. and Capdevila, J. H., 1997, An active site substitution, F87V, converts cytochrome P450BM3 into a regio-and stereoselective (14S,15R)-arachidonic acid epoxygenase. Journal of Biological Chemistry, 272, 1127-1135.
17. Guengerich, F. P., 1995, Human cytochrome P450 enzymes. In P. R. Ortiz de Montellano (ed.), Cytochrome P450 (New York: Plenum), pp. 473-535.
18. Guengerich, F. P. and Johnson, W. W., 1997, Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems. Biochemistry, 36, 14741-14750.
19. Guengerich, F. P., Kim, D.-H. and Iwasaki, M., 1991, Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168-179.
20. Halliwell, B. and Gutteridge., J. M. C., 1990, Role of free radicals and catalytic metal ions in human disease: an overview. Methods in Enzymology, 186, 1-85.
21. Hargreaves, M. B., Jones, B. C., Smith, D. A. and Gescher, A., 1994, Inhibition of p-nitrophenol hydroxylase in rat liver microsomes by small aromatic and heterocyclic molecules. Drug Metabolism and Disposition, 22, 806-810.
22. Ingelman-Sundberg, M., Johansson, I., Terelius, Y., Eliasson, E., Ekstrom, G., Buhler, R. and Lindros, K. O., 1993, Ethanol-inducible CYP2E1 : toxicological importance and regulation by nutrients. In D. V. Parke, C. Ioannides and R. Walker (eds), Food, Nutrition and Chemical Toxicity (London: Smith-Gordon), pp. 147-160.
23. Ioannides, C., Lewis, D. F. V. and Parke, D. V., 1995, Mechanisms of chemical carcinogenesis and molecular parametric analysis in the safety evaluation of chemicals. In C. Ioannides and D. F. V. Lewis (eds), Drugs, Diet and Disease, vol. 1 : Mechanistic Approaches to Cancer (Chichester: Ellis Horwood), pp. 1-46.
24. Johansson, I., Eliasson, E., Norsten, C. and Ingelman-Sundberg, M., 1986, Hydroxylation of acetone by ethanol-and acetone-inducible cytochrome P450 in liver microsomes and reconstituted membranes. FEBS Letters, 196, 59-64.
25. Koop, D. R., 1992, Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB Journal, 6, 726-730.
26. Koop, D. R. and Casazza, J. P., 1985, Identification of ethanol-inducible P450 isozyme 3a as the acetone and acetol monooxygenase of rabbit microsomes. Journal of Biological Chemistry, 260, 13607-13612.
27. Koop, D. R., Morgan, E. T., Torr, G. E. and Coon, M. J., 1982, Purification and characterization of a unique isozyme of cytochrome P450 from liver microsomes of ethanol-treated rabbits. Journal of Biological Chemistry, 257, 8472-8480.
28. Kukielka, E. and Cederbaum, A. I., 1994, DNA strand cleavage as a sensitive assay for the production of hydroxyl radicals by microsomes: role of cytochrome P4502E1 in the increased activity after ethanol treatment. Biochemical Journal, 302, 773-779.
29. Laetham, R. M., Balazy, M., Falck, J. R., Laetham, C. L. and Koop, D. R., 1993, Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. Journal of Biological Chemistry, 268, 12912-12918.
30. Levitt, M. and Perutz, M. F., 1988, Aromatic rings act as hydrogen bond acceptors. Journal of Molecular Biology, 201, 751-754.
31. Lewis, D. F. V., 1987, Quantitative structure-activity relationships in a series of alcohols exhibiting inhibition of cytochrome P450-mediated aniline hydroxylation. Chemico-Biological Interactions, 62, 271-280.
32. bm3). Xenobiotica, 25, 333-366.
33. Lewis, D. F. V., 1996, Cytochromes P450: Structure, Function and Mechanism (London: Taylor & Francis).
34. Lewis, D. F. V., 1998, The CYP2 family: models, mutants and interactions. Xenobiotica, 28, 617-661.
35. Lewis, D. F. V., Bird, M. G. and Parke, D. V., 1997b, Molecular modelling of CYP2E1 enzymes for rat, mouse and man: an explanation for species differences in butadiene metabolism and potential carcinogenicity, and rationalization of CYP2E substrate specificity. Toxicology, 118, 93-113.
36. Lewis, D. F. V., Brantom, P. G., Ioannides, C., Walker, R. and Parke, D. V., 1997a, Nitrosamine carcinogenesis: rodent assays, quantitative structure-activity relationships and human risk assessment. Drug Metabolism Reviews, 29, 1055-1078.
37. Lewis, D. F. V., Eddershaw, P. J., Tarbit, M. H. and Goldfarb, P. S., 1998b, Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chemico-Biological Interactions, 115, 175-199.
38. Lewis, D. F. V., Ioannides, C. and Parke, D. V., 1994, Interaction of a series of nitriles with the alcohol-inducible isoform of P450: computer analysis of structure-activity relationships. Xenobiotica, 24, 401-408.
39. Lewis, D. F. V. and Pratt, J. M., 1998, The cytochrome P450 catalytic cycle and mechanism of oxygenation. Drug Metabolism Reviews, 30, 739-786.
40. Lewis, D. F. V., Watson, E. and Lake, B. G., 1998a, Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutation Research, 410, 245-270.
41. BM3 haem domain complexed with the fatty acid substrate, palmitoleic acid. Nature Structural Biology, 4, 140-146.
42. Lijinsky, W., 1993, Life-span and cancer: the induction time of tumors in diverse animal species treated with nitrosodiethylamine. Carcinogenesis, 14, 2373-2375.
43. Liu, P. T., Ioannides, C., Shavila, J., Symons, A. M. and Parke, D. V., 1993, Effects of ether anaesthesia and fasting on various cytochromes P450 of rat liver and kidney. Biochemical Pharmacology, 45, 871-877.
44. Loizou, G. D., Urban, G., Dekant, W. and Anders, M. W., 1994, Gas-uptake pharmacokinetics of 2,2-dichloro-1,1,1-trifluoroethane (HCFC-123). Drug Metabolism and Disposition, 22, 511-517.
45. Lorenz, J., Glatt, H. R., Fleischmann, R., Ferlinz, R. and Oesch, F., 1984, Drug metabolism in man and its relationship to that in three rodent species: monooxygenase, epoxide hydrolase and glutathione S-transferase activities in subcellular fractions of lung and liver. Biochemical Medicine, 32, 43-56.
46. Mackman, R., Guo, Z., Guengerich, F. P. and Ortiz de Montellano, P. R., 1996, Active site topology of human cytochrome P450 2E1. Chemical Research in Toxicology, 9, 223-226.
47. Melnick, R. L. and Kohn, M. C., 1995, Mechanistic data indicate that 1,3-butadiene is a human carcinogen. Carcinogenesis, 16, 157-163.
48. Nakajima, T., Wang, R.-S., Elovaara, E., Park, S. S., Gelboin, H. V. and Vainio, H., 1993, Cytochrome P450-related differences between rats and mice in the metabolism of benzene, toluene and trichloroethylene in liver microsomes. Biochemical Pharmacology, 45, 1079-1085.
49. Nahri, L. O. and Fulco, A. J., 1986, Characterization of a catalytically self-sufficient 119,000-dalton cytochrome P450 monooxygenase induced by barbiturates in Bacillus megaterium. Journal of Biological Chemistry, 261, 7160-7169.
50. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C. and Nebert, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
51. Nelson, S. D., 1990, Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Seminars in Liver Disease, 10, 267-278.
52. Ono, S., Hatanaka, T., Hotta, H., Satoh, T., Gonzalez, F. J. and Tsutsu, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450: evaluation of in vitro metabolism using cDNA-expressed human P450 and human liver microsomes. Xenobiotica, 26, 681-693.
53. Parke, D. V., 1987, Activation mechanisms to chemical toxicity. Archives of Toxicology, 60, 5-15.
54. Parke, D. V., 1994, The cytochromes P450 and mechanisms of chemical carcinogenesis. Environmental Health Perspectives, 102, 852-853.
55. Parke, D. V. and Ioannides, C., 1990, Roles of cytochromes P450 in mouse liver tumor production. In D. E. Stevenson, R. M. McClain, J. A. Popp, T. G. Slaga, J. M. Ward and H. C. Pitot (eds), Mouse Liver Carcinogenesis : Mechanisms and Species Comparisons (New York : Alan Liss), pp. 215-230.
56. Parkinson, A., 1996, An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicologic Pathology, 24, 45-57.
57. Porter, T. D., 1994, Mutagenesis at a highly conserved phenylalanine in cytochrome P450 2E1 affects heme incorporation and catalytic activity. Biochemistry, 33, 5942-5946.
58. Raucy, J. L., Kraner, J. C. and Lasker, J. M., 1993, Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Critical Reviews in Toxicology, 23, 1-20.
59. Raucy, J. L., Lasker, J. M., Lieber, C. S. and Black, M., 1989, Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Archives of Biochemistry and Biophysics, 271, 270-283.
60. Raunio, H. and Pelkonen, O., 1995, Cancer genetics: genetic factors in the activation and inactivation of chemical carcinogens. In C. Ioannides and D. F. V. Lewis (eds), Drugs, Diet and Disease, vol. 1 : Mechanistic Approaches to Cancer (Chichester: Ellis Horwood), pp. 229-258.
61. BM3, a prototype for microsomal P450. Science, 261, 731-736.
62. Rendic, S. and Di Carlo, F. J., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metabolism Reviews, 29, 413-580.
63. Ronis, M. J. J., Lindros, K. O. and Ingelman-Sundberg, M., 1996, The CYP2E Subfamily. In C. Ioannides (ed.), Cytochromes P450 - Metabolic and Toxicological Aspects (Boca Raton: CRC Press), pp. 211-239.
64. 3 radical reactivity in the troposphere. Atmospheric Environment, 24A, 73-78.
65. Sangster, J., 1989, Octanol-water partition coefficients of simple organic compounds. Journal of Physical and Chemical Reference Data, 18, 1111-1229.
66. Sharma, R. K., Doig, M. V., Lewis, D. F. V. and Gibson, G. G., 1989, Role of hepatic and renal cytochrome P450 IVA1 in the metabolism of lipid substrates. Biochemical Pharmacology, 38, 3621-3629.
67. Shimizu, T., 1997, Diverse role of conserved aromatic amino acids in the electron transfer of cytochrome P450 catalytic functions: site-directed mutagenesis studies. Recent Research Developments in Pure and Applied Chemistry, 1, 169-175.
68. Smith, D. A., 1994, Chemistry and enzymology : their use in the prediction of human drug metabolism. European Journal of Pharmaceutical Sciences, 2, 69-71.
69. Smith, D. A., Ackland, M. J. and Jones, B. C., 1997, Properties of cytochrome P450 isoenzymes and their substrates. Part 2: Properties of cytochrome P450 substrates. Drug Discovery Today, 2, 479-486.
70. Stenlake, J. B., 1979, Foundations of Molecular Pharmacology, vol. 2: The Chemical Basis of Drug Action (London: Athlone).
71. Tan, Y., White, S. P., Paranawithana, S. R. and Yang, C. S., 1997, A hypothetical model for the active site of human cytochrome P4502E1. Xenobiotica, 27, 287-299.
72. Tassaneeyakul, W., Veronese, M. E., Birkett, D. J., Gonzalez, F. J. and Miners, J. O., 1993, Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochemical Pharmacology, 46, 1975-1981.
73. Terelius, Y., Lindros, K. O., Albano, E. and Ingelman-Sundberg, M., 1993, Isoenzyme specificity of cytochrome P450 mediated hepatotoxicity. Frontiers in Biotransformation, 8, 186-232.
74. Traylor, T. G. and Xu, F., 1988, Model reactions related to cytochrome P450. Effects of alkene structure on the rates of epoxide formation. Journal of the American Chemical Society, 110, 1953-1958.
75. Urban, G., Speerschnaider, P. and Dekant, W., 1994, Metabolism of the chlorofluorocarbon substitute 1,1-dichloro-2,2,2-trifluoroethane by rat and human liver microsomes. Chemical Research in Toxicology, 7, 170-176.
76. Vinter, J. G., Davis, A. and Saunders, M. R., 1987, Strategic approaches to drug design. I. An integrated software framework for molecular modelling. Journal of Computer-Aided Molecular Design, 1, 31-51.
77. Waller, C. L., Evans, M. V. and McKinney, J. D., 1996, Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. Drug Metabolism and Disposition, 24, 203-210.
78. Wang, M.-H., Wade, D., Chen, L., White, S. and Yang, C. S., 1995, Probing the active sites of rat and human cytochrome P450 2E1 with alcohols and carboxylic acids. Archives of Biochemistry and Biophysics, 317, 299-304.
79. Wiseman, H. and Halliwell, B., 1996, Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochemical Journal, 313, 17-29.
80. Yang, C. S., Yoo, J.-S. H., Ishizaki, H. and Hong, J., 1990, Cytochrome P450IIE1 : role in nitrosamine metabolism and mechanisms of regulation. Drug Metabolism Reviews, 22, 147-159.
81. Yin, H., Anders, M. W., Korzekwa, K. R., Higgins, L., Thummel, K. E., Kharasch, E. D. and Jones, J. P., 1995, Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. Proceedings of the National Academy of Sciences, USA, 92, 11076-11080.